25 results found.

Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lu Clinical Trial using positron emission tomography; computed tomography; intensity-modulated radiation therapy; carboplatin; paclitaxel

Albert Einstein College of Medicine of Yeshiva University - Recruiting 18 years or older.
- PET-Adjusted IMRT for NSCLC Trial (PAINT).
positron emission tomography; computed tomography; intensity-modulated radiation therapy; carboplatin; paclitaxel

Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Clinical Trial using bavituximab; Docetaxel; Placebo (for bavituximab)

Peregrine Pharmaceuticals - Recruiting 18 years or older.
- SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone as Second-Line Therapy in Patients With Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer.
bavituximab; Docetaxel; Placebo (for bavituximab)

Non-small Cell Lung Cancer Clinical Trial using Nivolumab; Gemcitabine; Cisplatin; Pemetrexed; Paclitaxel; Carboplatin; Bevacizumab; Erlotinib; Ipilimumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Multi-arm Phase I Safety Study of Nivolumab in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC).
Nivolumab; Gemcitabine; Cisplatin; Pemetrexed; Paclitaxel; Carboplatin; Bevacizumab; Erlotinib; Ipilimumab

Non-Small Cell Lung Cancer Clinical Trial using erlotinib; placebo; onartuzumab

Hoffmann-La Roche - Recruiting 18 years or older.
- A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH ERLOTINIB AS FIRST-LINE TREATMENT FOR PATIENTS WITH MET-POSITIVE UNRESECTABLE STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING AN ACTIVATING EGFR MUTATION.
erlotinib; placebo; onartuzumab

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using Selumetinib; Docetaxel; Placebo; Pegylated G-CSF

AstraZeneca - Recruiting 18 years or older.
- A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1).
Selumetinib; Docetaxel; Placebo; Pegylated G-CSF

Neoplasms,, Metastatic Cancer,, Non-Small Cell Lung Cancer, or Ad Clinical Trial using AZD6244; Docetaxel

AstraZeneca - Recruiting 20 years or older.
- A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given as a Monotherapy in Japanese Patients With Advanced Solid Malignancies, and When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV).
AZD6244; Docetaxel

Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lu Clinical Trial using HPPH; therapeutic conventional surgery; photodynamic therapy

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) With Temoporfin in Patients With Resectable Primary Non-Small Cell Lung Cancer (NSCLC) With Ipsilateral Thoracic Nodal (N1 or N2) or T3/T4 Disease.
HPPH; therapeutic conventional surgery; photodynamic therapy

Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lu Clinical Trial using photon beam radiation therapy; proton beam radiation therapy; paclitaxel; carboplatin; etoposide; cisplatin; quality-of-life assessment; questionnaire administration

Radiation Therapy Oncology Group - Recruiting 18 years or older.
- Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC.
photon beam radiation therapy; proton beam radiation therapy; paclitaxel; carboplatin; etoposide; cisplatin; quality-of-life assessment; questionnaire administration

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 65 years or older.
- Therapeutic Strategies Including Avastin as 1st Line Therapy in Elderly Patients Suffering From Advanced (IIIB/IV Stage) Non-squamous Non-small Cell Lung Cancer, in Routine Clinical Practice..

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using selumetinib; gemcitabine; cisplatin; carboplatin; pemetrexed

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC).
selumetinib; gemcitabine; cisplatin; carboplatin; pemetrexed

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using Selumetinib 75 mg; Docetaxel 75 mg/m2; Docetaxel 60 mg/m2; Placebo

AstraZeneca - Recruiting 18 years or older.
- A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV).
Selumetinib 75 mg; Docetaxel 75 mg/m2; Docetaxel 60 mg/m2; Placebo

Recurrent Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lu Clinical Trial using trametinib; carboplatin; paclitaxel; intensity-modulated radiation therapy; 3-dimensional conformal radiation therapy; image-guided radiation therapy; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-Small Cell Lung Cancer.
trametinib; carboplatin; paclitaxel; intensity-modulated radiation therapy; 3-dimensional conformal radiation therapy; image-guided radiation therapy; pharmacological study; laboratory biomarker analysis

Lung Cancer Clinical Trial using bevacizumab; emepepimut-S; carboplatin; cyclophosphamide; paclitaxel; radiation therapy

Eastern Cooperative Oncology Group - Recruiting 18 years or older.
- A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation.
bevacizumab; emepepimut-S; carboplatin; cyclophosphamide; paclitaxel; radiation therapy

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]; gemcitabine; cisplatin

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multiple Center, Open-label, Randomized Phase III Study to Evaluate the Efficacy and Safety of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as the First-line Treatment for Stage IIIB/IV NSCLC Patients With Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) in Their Tumor.
erlotinib [Tarceva]; gemcitabine; cisplatin

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial using PET/CT

National Cancer Institute, Naples - Recruiting 18 years or older.
- Study of the Role of Metabolic Response Measured by PET/CT Scan After 1 Cycle of Chemotherapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC).
PET/CT

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]; Placebo; Onartuzumab [MetMAb]

Hoffmann-La Roche - Recruiting 18 years or older.
- A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB (MetMAb) IN COMBINATION WITH ERLOTINIB AS SECOND- OR THIRD-LINE TREATMENT FOR PATIENTS WITH MET-POSITIVE INCURABLE STAGE IIIB/IV NON-SMALL CELL LUNG CANCER.
erlotinib [Tarceva]; Placebo; Onartuzumab [MetMAb]

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial using Gemcitabine; Pemetrexed; Cisplatin

National Cancer Institute, Naples - Recruiting 70 years or older.
- A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC..
Gemcitabine; Pemetrexed; Cisplatin

Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell L Clinical Trial using therapeutic lymphadenectomy; stereotactic body radiation therapy; quality-of-life assessment

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Pilot Study of Stereotactic Body Radiation Therapy (SBRT) After TEMLA for Stage III and IV (Oligometastatic) Non-Small Cell Lung Cancer.
therapeutic lymphadenectomy; stereotactic body radiation therapy; quality-of-life assessment

Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell L Clinical Trial using entinostat; azacitidine; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Study of Entinostat in Combination With 5-Azacytidine in Patients With Recurrent Advanced Non-Small Cell Lung Cancer.
entinostat; azacitidine; pharmacological study; laboratory biomarker analysis

Lung Cancer Clinical Trial using carboplatin; cisplatin; gemcitabine hydrochloride

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A British Thoracic Oncology Group Phase III Trial of Gemcitabine Plus Cisplatin at 80mg/m Versus Gemcitabine Plus Carboplatin At 50 mg/m Versus Gemcitabine Plus Carboplatin AUC 6 in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC).
carboplatin; cisplatin; gemcitabine hydrochloride

NSCLC, EGFR Gene Amplification, Advanced Cancer, Stage IIIB NSCLC Clinical Trial using Gefitinib and Metformin; Gefitinib and placebo

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University - Recruiting 18 years to 75 years.
- A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gefitinib and Metformin in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer.
Gefitinib and Metformin; Gefitinib and placebo

Lung Cancer Clinical Trial using Pazopanib

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab.
Pazopanib

Non-small Cell Lung Cancer Stage IIIB, or Toxicity Due to Chemoth Clinical Trial using chemotherapy & WBH

Xijing Hospital - Recruiting 18 years to 75 years.
- A Randomized Contrasted Polycentric Clinical Study About Chemotherapy Combined With Whole-body Hyperthermia(WBH)to Treat Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC).
chemotherapy & WBH

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous, or Carcinoma Clinical Trial using Docetaxel; Oxaliplatin

Korean South West Oncology Group - Recruiting 18 years or older.
- A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment.
Docetaxel; Oxaliplatin

Lung Cancer Clinical Trial using erlotinib hydrochloride; sorafenib tosylate; DNA analysis; mutation analysis; polymerase chain reaction; protein analysis; protein expression analysis; immunohistochemistry staining method; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Multicenter, Open-label, Phase II Study of Sorafenib in Combination With Erlotinib in Non-small Cell Lung Cancer (NSCLC) Refractory to One or Two Prior Chemotherapy Regimens.
erlotinib hydrochloride; sorafenib tosylate; DNA analysis; mutation analysis; polymerase chain reaction; protein analysis; protein expression analysis; immunohistochemistry staining method; laboratory biomarker analysis